In CRC harboring BRAFV600E mutations, which shows a low response rate to BRAF inhibitors due to the emergence of resistance, the novel series of hydroxamate acid- and 2-aminopyridinyl-containing compounds such as BRAF and HDAC dual-targeted inhibitors were investigated. This evidence concerns the gene BRAF and colorectal carcinoma.